Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Korea Head Rebuffs Speculation About Hostile Takeover Of Dong-A

This article was originally published in PharmAsia News

Executive Summary

SEOUL - GlaxoSmithKline said it is not pursuing a hostile takeover of South Korea's leading drug firm Dong-A Pharmaceutical despite market speculation triggered when the multinational company bought 9.9 percent of Dong-A's equity in May

You may also be interested in...



GSK Korea Moving Ahead To Sell Avandia With Korea's Dong-A Despite U.S. FDA Safety Study

SEOUL - Immediately following a joint U.S. FDA advisory committee vote July 14 recommending that Avandia remain on the market, GlaxoSmithKline Korea said its plan to co-market its diabetes medicine with South Korea's Dong-A Pharmaceutical will proceed as scheduled in the second half of the year

GSK Korea Moving Ahead To Sell Avandia With Korea's Dong-A Despite U.S. FDA Safety Study

SEOUL - Immediately following a joint U.S. FDA advisory committee vote July 14 recommending that Avandia remain on the market, GlaxoSmithKline Korea said its plan to co-market its diabetes medicine with South Korea's Dong-A Pharmaceutical will proceed as scheduled in the second half of the year

South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment

SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended

Latest News
See All
UsernamePublicRestriction

Register

SC075315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel